# Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP167 in Adults With Mixed Dyslipidemia

Study · id `cardio:ct-nct07799129` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07799129](<https://clinicaltrials.gov/study/NCT07799129>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07799129

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 144 participants.

## Technical summary

Registry record NCT07799129. Randomized; double masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2027-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 144 participants (planned count; ClinicalTrials.gov record NCT07799129, source copy `cardio:ctgov-nct07799129-2026-09-02`, retrieved 2026-10-31)
- Planned start: 2026-11 (anticipated) (ClinicalTrials.gov record NCT07799129, source copy `cardio:ctgov-nct07799129-2026-09-02`, retrieved 2026-10-31)
- Primary completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT07799129, source copy `cardio:ctgov-nct07799129-2026-09-02`, retrieved 2026-10-31)
- Completion: 2028-04 (anticipated) (ClinicalTrials.gov record NCT07799129, source copy `cardio:ctgov-nct07799129-2026-09-02`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07799129, source copy `cardio:ctgov-nct07799129-2026-09-02`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07799129-2026-09-02`, retrieved 2026-10-31)

## The registry's words

- Brief title: Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP167 in Adults With Mixed Dyslipidemia
- Condition: Mixed Dyslipidemia
- Intervention (Drug): EDP167 100mg
- Intervention (Drug): EDP167 200mg
- Intervention (Drug): EDP167 300mg
- Lead sponsor: Eddingpharm (Zhuhai) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

## Provenance

Content hash: 3df89ad65ef3e2ed5a72298e734280e146513591deecf8347f0644e8f3038812
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
